A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial-Reference-Cited by-同舟云学术

A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial

Published:2001-12 Issue:12 Volume:23 Page:1969-1983
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

DuBiner Harvey B,Mroz Michael,Shapiro Aron M,Dirks Monte S

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference35 articles.

1. The role of medical therapy in the rank order of glaucoma treatment;Wilensky;Curr Opin Ophthalmol,1999

2. Pharmacological therapy for glaucoma: A review;Hoyng;Drugs,2000

3. Antiglaucoma medications: A review of safety and tolerability issues related to their use;Schuman;Clin Ther,2000

4. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension;LeBlanc;Ophthalmology,1998

5. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: A randomized clinical trial;Javitt;J Glaucoma,2000

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Utility Analysis of a Medication Adherence-Enhancing Educational Intervention for Glaucoma;Ophthalmology Glaucoma;2023-07

2. Cost-Utility Analysis of Glaucoma Medication Adherence;Ophthalmology;2020-05

3. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine;Human & Experimental Toxicology;2020-04-29

4. Prospective randomized clinical trial on the effects of latanoprost, travoprost and bimatoprost on latanoprost non-responders;Journal Français d'Ophtalmologie;2019-10

5. Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety;Vestnik oftal'mologii;2019